Stockscreener 앱 받기
29.88
0.88%
0.26
전일 마감가:
$29.62
열려 있는:
$29.57
하루 거래량:
69,374
Relative Volume:
0.13
시가총액:
$1.39B
수익:
$722.68M
순이익/손실:
$134.71M
주가수익비율:
11.19
EPS:
2.67
순현금흐름:
$109.94M
1주 성능:
-1.09%
1개월 성능:
+41.01%
6개월 성능:
-4.48%
1년 성능:
-36.25%
1일 변동 폭
$29.43
$30.05
1주일 범위
$29.42
$30.99
52주 변동 폭
$20.39
$53.95
Amphastar Pharmaceuticals Inc Stock (AMPH) Company Profile
명칭
Amphastar Pharmaceuticals Inc
전화
909-980-9484
주소
11570 SIXTH STREET, RANCHO CUCAMONGA, CA
AMPH을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMPH
Amphastar Pharmaceuticals Inc
|
29.88 | 1.38B | 722.68M | 134.71M | 109.94M | 2.67 |
|
ZTS
Zoetis Inc
|
158.16 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.32 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.835 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.09 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
308.55 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Amphastar Pharmaceuticals Inc Stock (AMPH) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-12 | 업그레이드 | Needham | Hold → Buy |
| 2025-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-11-22 | 개시 | Wells Fargo | Equal Weight |
| 2024-03-05 | 개시 | JP Morgan | Overweight |
| 2023-11-17 | 개시 | BofA Securities | Neutral |
| 2023-07-25 | 재개 | Jefferies | Buy |
| 2022-10-21 | 재개 | Jefferies | Buy |
| 2022-07-29 | 개시 | CapitalOne | Overweight |
| 2022-01-07 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-01-08 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-10-05 | 업그레이드 | Northland Capital | Market Perform → Outperform |
| 2020-05-01 | 개시 | Northland Capital | Outperform |
| 2019-03-13 | 다운그레이드 | Needham | Buy → Hold |
| 2019-03-13 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
| 2018-08-10 | 재확인 | Needham | Buy |
| 2018-03-13 | 재확인 | Needham | Buy |
| 2017-12-01 | 재확인 | Needham | Buy |
| 2017-11-09 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2017-09-27 | 재확인 | Needham | Buy |
| 2017-03-14 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2016-08-09 | 재확인 | Needham | Buy |
| 2016-05-10 | 재확인 | Needham | Buy |
| 2016-02-19 | 개시 | Wells Fargo | Outperform |
| 2015-06-19 | 재확인 | Needham | Buy |
| 2015-06-03 | 개시 | Raymond James | Strong Buy |
| 2014-07-21 | 개시 | Needham | Buy |
모두보기
Amphastar Pharmaceuticals Inc 주식(AMPH)의 최신 뉴스
Connor Clark & Lunn Investment Management Ltd. Reduces Stock Position in Amphastar Pharmaceuticals, Inc. $AMPH - MarketBeat
Amphastar Pharmaceuticals Enters Strategic Licensing Agreement - MSN
Published on: 2025-08-18 07:29:06 - sundaytimes.kr
Amphastar raised to Buy at Needham on iron sucrose injection approval - MSN
Amphastar Pharmaceuticals (NASDAQ:AMPH) Upgraded to Buy at Needham & Company LLC - MarketBeat
Is It Too Late to Sell Amphastar Pharmaceuticals Inc.Weekly Profit Analysis & AI Enhanced Execution Alerts - sundaytimes.kr
Drawdown in Amphastar Pharmaceuticals Inc. May Be Nearing EndJuly 2025 Snapshot & Real-Time Stock Entry Alerts - newsimpact.co.kr
Dextrose Injection Market Size, Share, Emerging Demands, - openPR.com
Amphastar boosts pipeline with exclusive licensing deal from Nanjing Anji - MSN
How does Amphastar Pharmaceuticals Inc. perform in inflationary periods2025 Technical Overview & AI Powered Buy and Sell Recommendations - thegnnews.com
5 Insightful Analyst Questions From Amphastar Pharmaceuticals’s Q2 Earnings Call - TradingView
Amphastar Pharmaceuticals (NASDAQ:AMPH) Shares Up 12.1%Still a Buy? - MarketBeat
Amphastar and Anji make licence agreement for three new peptides - Yahoo Finance
Amphastar Pharmaceuticals Q2 Earnings Call Highlights: Strong BAQSIMI Sales, Manufacturing Expansion, and Regulatory Progress, but Revenue Decline and Competition Challenges. - AInvest
Amphastar Pharmaceuticals’ Mixed Earnings Call Highlights - TipRanks
Amphastar Pharmaceuticals Gets Upgrade to Buy at Needham on AMP-002 Approval - AInvest
Amphastar Pharmaceuticals Upgraded to Buy by Needham Analyst - AInvest
Amphastar Pharmaceuticals, QuidelOrtho, Integra LifeSciences, Select Medical, and Regeneron Stocks Trade Up, What You Need To Know - Yahoo Finance
Amphastar Pharmaceuticals Secures FDA Approval for Iron Sucrose Injection, Sets Sights on Major Sales Momentum - AInvest
Amphastar Secures FDA Nod For Iron Sucrose Injection, Analysts Eye Major Sales Momentum - Benzinga
Amphastar Soars 11% on Intraday Surge: What’s Fueling the Momentum? - AInvest
Amphastar Pharmaceuticals upgraded to Buy by Needham after FDA approval for iron sucrose injection. - AInvest
Amphastar stock gains after licensing deal for three peptide therapies By Investing.com - Investing.com Canada
Amphastar Pharmaceuticals: Strategic Positioning and Robust Pipeline Justify Buy Rating - TipRanks
Needham upgrades Amphastar Pharmaceuticals stock to Buy on iron sucrose approval - Investing.com Canada
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Amphastar licenses three peptide therapies in oncology, ophthalmology deal By Investing.com - Investing.com South Africa
Amphastar licenses three peptide therapies in oncology, ophthalmology deal - Investing.com
Amphastar gets FDA nod for generic iron sucrose injection - MSN
Amphastar Shares Rise Following FDA Approval of Generic Iron Sucrose Injection - MSN
Amphastar Pharmaceuticals, Inc. Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd - MarketScreener
Amphastar Pharmaceuticals Bolsters Proprietary Pipeline Through Exclusive Licensing Agreement with Nanjing Anji Biotechnology Co., Ltd. - ACCESS Newswire
AMPH Q2 Deep Dive: BAQSIMI Momentum, Margin Pressures, and Pipeline Milestones - Yahoo Finance
Primatene Mist Sales Flat As Amphastar Plans Production Expansion To Support Pipeline - insights.citeline.com
Amphastar Pharmaceuticals Receives FDA Approval for Generic Iron Sucrose Injection - AInvest
FDA Approvals for Iron Sucrose Products by Viatris, Amphastar Pharmaceuticals - AInvest
Amphastar Pharmaceuticals (AMPH) stock surges 10.4% on FDA approval for generic Iron Sucrose Injection treatment for iron deficiency anemia. - AInvest
Why Is Amphastar Pharmaceuticals (AMPH) Stock Soaring Today - Yahoo Finance
FDA OKs Generic Iron Sucrose for CKD Anemia - Conexiant
Amphastar Soars 14.36% on FDA Approval: A Game-Changer or Fleeting Rally? - AInvest
Amphastar stock rises after FDA approves generic iron sucrose injection By Investing.com - Investing.com Canada
FDA approves Amphastar’s iron sucrose injection for anemia treatment By Investing.com - Investing.com Nigeria
FDA approves Amphastar’s iron sucrose injection for anemia treatment - Investing.com
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP - ACCESS Newswire
18,358 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by XTX Topco Ltd - MarketBeat
Amphastar Pharmaceuticals (AMPH) Q2 Earnings and Revenues Beat Estimates - msn.com
Utah Medical Products Reports Q2 Decline - AOL.com
Amphastar Pharmaceuticals (NASDAQ:AMPH) Price Target Cut to $25.00 by Analysts at Piper Sandler - MarketBeat
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Q2 2025 Earnings Call Transcript - Insider Monkey
Pfizer beats in Q2 earnings, reaffirms 2025 outlook [Video] - AOL.com
Technical Models Suggest Amphastar Pharmaceuticals Inc. May Rebound Soon - beatles.ru
Amphastar Pharmaceuticals Inc (AMPH) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.32%
0.13%
자본화:
|
볼륨(24시간):